Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shanghai Pioneer Holding Ltd (1345.HK)
Shanghai, CN
China Pioneer Pharma Holdings Limited operates as an investment holding company, primarily focusing on the marketing, promotion, and distribution of pharmaceutical goods and medical devices within mainland China. The firm maintains an extensive portfolio of pharmaceutical products addressing diverse therapeutic areas, including ophthalmology, pain management, cardiovascular health, immunology, gynecology, and gastroenterology. Its medical device offerings encompass solutions for ophthalmology, orthopedics, dentistry, and wound care. The company supplies its products to a wide client base, including hospitals, various medical institutions, and pharmacies. Additionally, it engages in the sale of supporting tools, leases related equipment, provides dental apparatus, and distributes imported prescription products under license. Established in 1996, China Pioneer Pharma Holdings Limited is headquartered in Shanghai, PRC, and functions as a subsidiary of Pioneer Pharma (BVI) Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.33% | +1.78% | +1.33% | +1.78% | +10.10% | -2.97% | +9.05% | -8.03% | +143.62% | +30.86% | -40.36% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%-16.2% Q4'25: -23.3% (vs Q4'23)
-
EPS growth Medical - Pharmaceuticals: +20.2%-23.7% Q4'25: +0.0% (vs Q4'23)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+13.8% Q4'25: +21.6% (vs Q4'23)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+10.9% ★ Q4'25: +11.4% (vs Q4'23)
-
ROIC Medical - Pharmaceuticals: +6.1%+10.4% ★ Q4'25: +21.2% (vs Q4'23)
-
Share dilution Medical - Pharmaceuticals: +0.0%-1.0% ★ Q4'25: -3.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×0.70× ★ Q4'25: 0.35× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
|---|---|---|---|---|---|---|
| Revenue |
1.27B
est: 1.01B (+26.2%)
|
1.54B
est: 1.28B (+20.5%)
|
1.46B
est: 1.36B (+7.5%)
|
1.79B
est: 1.46B (+22.7%)
|
2.15B
est: 2.12B (+1.5%)
|
1.62B
est: 2.52B (-35.4%)
|
| EBITDA |
287.65M
est: 130.12M (+121.1%)
|
291.86M
est: 260.14M (+12.2%)
|
243.63M
est: 237.51M (+2.6%)
|
255.74M
est: 158.65M (+61.2%)
|
292.91M
est: 211.05M (+38.8%)
|
157.74M
est: 324.58M (-51.4%)
|
| EBIT |
285.17M
est: 119.11M (+139.4%)
|
318.83M
est: 295.30M (+8.0%)
|
226.75M
est: 280.06M (-19.0%)
|
287.87M
est: 229.62M (+25.4%)
|
311.62M
est: 276.49M (+12.7%)
|
108.49M
est: 297.13M (-63.5%)
|
| Net Income |
238.37M
est: 222.37M (+7.2%)
|
261.72M
est: 240.85M (+8.7%)
|
174.30M
est: 219.28M (-20.5%)
|
237.45M
est: 156.56M (+51.7%)
|
278.93M
est: 200.73M (+39.0%)
|
84.60M
|
| SGA |
135.33M
est: 365.29M (-63.0%)
|
207.70M
est: 136.28M (+52.4%)
|
202.12M
est: 177.39M (+13.9%)
|
350.86M
est: 192.42M (+82.3%)
|
436.83M
est: 309.26M (+41.2%)
|
474.01M
est: 911.21M (-48.0%)
|
| EPS |
0.23
est: 0.19 (+20.4%)
|
0.20
est: 0.19 (+6.6%)
|
0.13
est: 0.17 (-23.2%)
|
0.18
est: 0.14 (+31.3%)
|
0.22
|
0.07
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-05 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-04 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 31.4K | 0.28% |
| 2 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 34.4K | 0.33% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 8.9K | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Zhang Xinzhou Li | Executive Chairman | 3M | male |
| Yuewen Yang | Chief Executive Officer & Executive Director | 782.4K | male |
| Jie Wang | Director of Personnel | — | — |
| Ka Man Ng | Company Secretary | — | female |
| Yi Xue | Chief Financial Officer | — | male |
| Yong Xiang Zheng | General Manager of Investment Department | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1345.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
